Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

HALO

Halozyme Therapeutics Inc.

Apr 24 • 10:44AM ET

39.32

Dollar change +0.35
Percentage change 0.90	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IJH VB IWM VXF VBK IWO FBT IBB IJK

Index	RUT	P/E	18.64	EPS (ttm)	2.11	Insider Own	1.03%	Shs Outstand	126.77M	Perf Week	3.42%
Market Cap	5.00B	Forward P/E	8.84	EPS next Y	4.45	Insider Trans	-8.40%	Shs Float	125.74M	Perf Month	-2.72%
Income	281.59M	PEG	0.75	EPS next Q	0.69	Inst Own	98.77%	Short Float	6.27%	Perf Quarter	12.18%
Sales	829.25M	P/S	6.02	EPS this Y	27.24%	Inst Trans	3.73%	Short Ratio	7.49	Perf Half Y	13.09%
Book/sh	0.66	P/B	59.48	EPS next Y	26.26%	ROA	15.75%	Short Interest	7.89M	Perf Year	17.23%
Cash/sh	2.64	P/C	14.87	EPS next 5Y	25.00%	ROE	222.07%	52W Range	29.85 - 45.00	Perf YTD	6.39%
Dividend Est.	-	P/FCF	13.38	EPS past 5Y	-	ROI	17.79%	52W High	-12.62%	Beta	1.26
Dividend TTM	-	Quick Ratio	5.50	Sales past 5Y	41.16%	Gross Margin	67.91%	52W Low	31.73%	ATR (14)	0.95
Dividend Ex-Date	-	Current Ratio	6.64	EPS Y/Y TTM	44.87%	Oper. Margin	40.71%	RSI (14)	49.96	Volatility	2.06% 2.31%
Employees	373	Debt/Eq	18.27	Sales Y/Y TTM	25.62%	Profit Margin	33.96%	Recom	1.33	Target Price	50.50
Option/Short	Yes / Yes	LT Debt/Eq	17.89	EPS Q/Q	56.52%	Payout	0.00%	Rel Volume	0.32	Prev Close	38.97
Sales Surprise	-0.42%	EPS Surprise	2.68%	Sales Q/Q	26.75%	Earnings	Feb 20 AMC	Avg Volume	1.05M	Price	39.32
SMA20	-0.55%	SMA50	-0.65%	SMA200	1.30%	Trades		Volume	78,803	Change	0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50
Sep-14-20	Resumed	JP Morgan	Overweight	$28
Jul-01-20	Initiated	The Benchmark Company	Buy	$39
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight	$18 → $27
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform	$17 → $24
Jan-08-20	Initiated	Goldman	Buy	$24

Show Previous Ratings

Apr-23-24 08:30AM	Halozyme to Report First Quarter 2024 Financial and Operating Results (PR Newswire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 12:45PM	Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-04-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
06:40AM	Loading…
Mar-29-24 06:40AM	The 3 Best Biotech Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-21-24 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report? (Zacks)
Mar-19-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Mar-14-24 01:24AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
Mar-12-24 02:05AM	Should You Hold Halozyme Therapeutics (HALO)? (Insider Monkey)
Mar-09-24 01:07PM	5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 03:15AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Feb-27-24 08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-21-24 11:26AM	Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag (Zacks) +6.56%
09:00AM	Loading…
09:00AM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:56AM	Q4 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 05:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics (Zacks)
05:10PM	Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates (Zacks)
04:36PM	Halozyme Therapeutics Inc (HALO) Reports Strong Year-Over-Year Growth in Q4 and Full Year 2023 ... (GuruFocus.com)
04:15PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Feb-14-24 09:15AM	Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
06:49AM	Halozyme Therapeutics (HALO) Underperformed Despite Strong Outlook (Insider Monkey)
Feb-13-24 10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-08-24 04:30PM	Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results (PR Newswire)
Jan-29-24 04:15PM	Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
Jan-26-24 09:45AM	Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jan-25-24 05:29PM	3 Biotech Stocks to Sell in January Before They Crash and Burn (InvestorPlace)
Jan-24-24 12:10PM	Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive? (Zacks)
09:40AM	Loading…
Jan-22-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jan-18-24 05:01PM	Halozyme Therapeutics Inc's SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares (GuruFocus.com)
08:30AM	Halozyme Announces argenx Received Approval in Japan for VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE for Generalized Myasthenia Gravis (PR Newswire)
Jan-17-24 04:01AM	Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jan-16-24 08:15AM	Halozyme Announces Takeda Receives FDA Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire) +5.61%
01:15AM	Halozyme Announces Roche Receives European Commission Approval of Tecentriq SC with ENHANZE Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types (PR Newswire)
Jan-12-24 09:25AM	Halozyme to Host Investor Business Forum and Long-Term Outlook Call (PR Newswire)
Jan-10-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Dec-15-23 03:01PM	Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ... (GuruFocus.com)
Dec-14-23 12:45PM	3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks) -6.29%
Dec-08-23 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Dec-06-23 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report? (Zacks)
Dec-05-23 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-27-23 08:00AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Nov-20-23 12:45PM	Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now (Zacks)
Nov-17-23 07:03AM	Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ... (GuruFocus.com)
Nov-16-23 09:55AM	Can Halozyme Therapeutics (HALO) Climb 28.72% to Reach the Level Wall Street Analysts Expect? (Zacks)
09:00AM	Halozyme Announces argenx Receives European Commission Approval of VYVGART SC with ENHANZE for Generalized Myasthenia Gravis (PR Newswire)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace)
04:43PM	Under the Microscope: 3 Biotech Stocks Pioneering Tomorrows Cures (InvestorPlace)
Nov-08-23 05:19AM	3 Promising Biotech Stocks Flying Under the Radar (InvestorPlace) -5.28%
Nov-07-23 11:22AM	Q3 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.04%
11:21AM	Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag (Zacks)
11:06AM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 06:00PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics (Zacks)
05:25PM	Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates (Zacks)
05:10PM	Halozyme Therapeutics Inc (HALO) Reports 15% YoY Increase in Q3 Royalty Revenue, Raises 2023 ... (GuruFocus.com)
04:27PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
07:30AM	Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE Technology in Alzheimer's Disease (PR Newswire)
Oct-30-23 06:35PM	Halozyme To Report Third Quarter 2023 Financial and Operating Results (PR Newswire)
Oct-27-23 08:47AM	Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune (InvestorPlace)
Oct-20-23 12:08PM	12 Cheap Biotech Stocks Smart Investors Are Piling Into (Insider Monkey)
05:36AM	Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals (Zacks)
Oct-19-23 07:32AM	UPDATE 2-Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial (Reuters)
07:15AM	Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma (PR Newswire)
Oct-18-23 05:01AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ... (GuruFocus.com)
Oct-16-23 03:05PM	Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference (PR Newswire)
08:00AM	Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery (PR Newswire)
Oct-13-23 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Sep-20-23 05:01AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ... (GuruFocus.com)
Sep-07-23 11:30AM	Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound? (Zacks)
09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Sep-05-23 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Sep-01-23 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-31-23 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Aug-30-23 07:17AM	Should You Remain Confident in Halozyme Therapeutics (HALO)? (Insider Monkey)
Aug-29-23 04:50AM	Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain (PR Newswire)
Aug-09-23 12:19PM	Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised (Zacks)
Aug-08-23 09:00PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
05:40PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates (Zacks)
04:32PM	Halozyme Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Jul-28-23 12:00PM	15 Best Russell 2000 Stocks To Buy Now (Insider Monkey)
06:14AM	Drugmakers go under the skin, skirting early US Medicare price negotiations (Reuters)
06:00AM	FOCUS-Drugmakers go under the skin, skirting early US Medicare price negotiations (Reuters)
Jul-25-23 08:30AM	Halozyme To Report Second Quarter 2023 Financial and Operating Results (PR Newswire)
Jul-18-23 05:39AM	Halozyme Therapeutics (HALO) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-17-23 01:15AM	Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire) +5.36%
Jul-14-23 10:56AM	Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study (Zacks)
Jul-13-23 01:15AM	Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis (PR Newswire) +5.43%
Jun-27-23 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jun-26-23 07:08AM	Should You Hold Halozyme Therapeutics (HALO)? (Insider Monkey)
Jun-21-23 08:00PM	HALO: Raising target price to $38.00 (Argus Research)
Jun-20-23 06:30PM	Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis (PR Newswire)
Jun-12-23 08:53AM	Those who invested in Halozyme Therapeutics (NASDAQ:HALO) five years ago are up 80% (Simply Wall St.)
Jun-08-23 11:30AM	Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-06-23 08:30AM	Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
May-25-23 04:15PM	7 Meme Stocks to Buy Before They Soar to New Heights in 2023 (InvestorPlace)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Sale	38.49	10,000	384,890	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Sale	38.35	10,000	383,500	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 26 '24	Option Exercise	11.20	11,618	130,160	168,176	Mar 26 07:38 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Option Exercise	10.66	10,000	106,638	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Sale	42.27	10,000	422,730	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Option Exercise	12.07	10,000	120,700	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Sale	41.64	10,000	416,370	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Option Exercise	8.11	7,471	60,590	164,029	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Sale	39.55	10,000	395,463	156,558	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '24	Sale	39.95	10,000	399,460	159,087	Feb 28 06:49 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '24	Option Exercise	0.00	37,884	0	685,814	Feb 20 06:49 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Feb 16 '24	Option Exercise	0.00	4,796	0	14,257	Feb 20 06:55 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,422	0	18,344	Feb 20 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,376	0	171,247	Feb 20 06:59 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '24	Option Exercise	0.00	3,386	0	160,529	Feb 16 05:47 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '24	Option Exercise	0.00	1,254	0	11,345	Feb 16 05:41 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '24	Option Exercise	0.00	13,092	0	651,096	Feb 16 05:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 10 '24	Option Exercise	0.00	31,281	0	654,947	Feb 13 04:12 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 10 '24	Option Exercise	0.00	2,502	0	11,568	Feb 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 10 '24	Option Exercise	0.00	8,133	0	160,044	Feb 13 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Jan 03 '24	Option Exercise	0.00	7,611	0	12,418	Jan 05 04:04 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Option Exercise	12.07	10,000	120,700	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Sale	40.39	10,000	403,940	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Option Exercise	13.55	10,000	135,547	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Sale	39.63	10,000	396,322	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Option Exercise	13.81	10,000	138,100	161,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Sale	39.79	10,000	397,880	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Option Exercise	14.32	10,000	143,173	160,203	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Sale	39.08	10,000	390,790	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Option Exercise	19.98	10,000	199,800	161,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Sale	36.52	10,000	365,200	151,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Option Exercise	19.98	10,000	199,800	161,911	Sep 19 04:09 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Sale	39.10	10,000	390,980	151,911	Sep 19 04:09 PM
Torley Helen	PRESIDENT AND CEO	Aug 31 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 31 '23	Sale	42.82	10,000	428,170	623,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 30 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 30 '23	Sale	42.85	10,000	428,540	623,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 29 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 29 '23	Sale	42.40	10,000	424,020	623,666	Aug 31 05:35 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 22 '23	Option Exercise	19.68	10,000	196,778	159,986	Aug 23 05:08 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 22 '23	Sale	42.41	10,000	424,070	151,911	Aug 23 05:08 PM
Torley Helen	PRESIDENT AND CEO	Aug 17 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 17 '23	Sale	43.18	10,000	431,820	623,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 16 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 16 '23	Sale	43.53	10,000	435,320	623,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '23	Sale	43.77	10,000	437,680	623,666	Aug 17 05:29 PM
Daly James M	Director	Aug 14 '23	Sale	43.74	10,000	437,410	20,503	Aug 15 04:04 PM
Daly James M	Director	Aug 11 '23	Sale	43.71	10,000	437,110	30,503	Aug 15 04:04 PM
Torley Helen	PRESIDENT AND CEO	Jul 27 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 27 '23	Sale	43.79	10,000	437,900	623,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 26 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 26 '23	Sale	42.69	10,000	426,890	623,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 25 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 25 '23	Sale	42.80	10,000	427,960	623,666	Jul 27 04:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 18 '23	Option Exercise	15.30	20,000	306,098	151,911	Jul 19 04:10 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 18 '23	Sale	40.43	10,000	404,300	141,911	Jul 19 04:10 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 21 '23	Option Exercise	18.41	10,000	184,100	151,911	Jun 22 06:20 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 21 '23	Sale	36.00	10,000	360,000	141,911	Jun 22 06:20 PM

Open in Screener

ACAD

Acadia Pharmaceuticals Inc

Apr 24 • 10:44AM ET

16.71

Dollar change -0.03
Percentage change -0.15	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ACAD Acadia Pharmaceuticals Inc daily Stock Chart

Held by: VTI VB IWM FBT VXF VBK IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.38	Insider Own	0.80%	Shs Outstand	164.65M	Perf Week	-2.77%
Market Cap	2.75B	Forward P/E	13.25	EPS next Y	1.26	Insider Trans	-6.29%	Shs Float	163.46M	Perf Month	-6.31%
Income	-61.29M	PEG	-	EPS next Q	0.05	Inst Own	96.99%	Short Float	6.85%	Perf Quarter	-38.53%
Sales	726.44M	P/S	3.79	EPS this Y	273.75%	Inst Trans	0.91%	Short Ratio	6.20	Perf Half Y	-24.98%
Book/sh	2.62	P/B	6.37	EPS next Y	96.23%	ROA	-9.17%	Short Interest	11.20M	Perf Year	-17.01%
Cash/sh	2.66	P/C	6.28	EPS next 5Y	-	ROE	-14.73%	52W Range	16.60 - 33.99	Perf YTD	-46.62%
Dividend Est.	-	P/FCF	165.41	EPS past 5Y	28.03%	ROI	-12.78%	52W High	-50.83%	Beta	0.41
Dividend TTM	-	Quick Ratio	2.28	Sales past 5Y	27.73%	Gross Margin	94.27%	52W Low	0.69%	ATR (14)	0.61
Dividend Ex-Date	-	Current Ratio	2.42	EPS Y/Y TTM	71.78%	Oper. Margin	-10.10%	RSI (14)	29.04	Volatility	2.78% 2.89%
Employees	598	Debt/Eq	0.13	Sales Y/Y TTM	40.45%	Profit Margin	-8.44%	Recom	1.71	Target Price	29.09
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	206.75%	Payout	-	Rel Volume	0.29	Prev Close	16.74
Sales Surprise	3.24%	EPS Surprise	-3.08%	Sales Q/Q	69.27%	Earnings	Feb 27 AMC	Avg Volume	1.80M	Price	16.71
SMA20	-5.12%	SMA50	-19.02%	SMA200	-32.17%	Trades		Volume	119,164	Change	-0.15%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17
Aug-08-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Aug-05-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Jun-21-22	Downgrade	Jefferies	Buy → Underperform	$25 → $10
Jun-16-22	Upgrade	Jefferies	Hold → Buy	$25
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy	$30 → $31
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$36

Show Previous Ratings

Apr-22-24 09:04AM	Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada (Business Wire)
Apr-20-24 09:15AM	5 Best Healthcare Stocks to Buy Under $20 (Insider Monkey)
Apr-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-24 04:05PM	Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-11-24 02:10PM	3 Pharma Stocks to Sell in April Before They Crash & Burn (InvestorPlace)
01:28AM	Loading…
Apr-10-24 01:28AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares (GuruFocus.com)
Apr-02-24 04:05PM	Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development (Business Wire)
Apr-01-24 04:05PM	Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-28-24 11:30AM	Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? (Zacks)
02:00AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares (GuruFocus.com)
Mar-20-24 01:31PM	Billionaire Steve Cohen and Insiders are Buying These 5 Stocks (Insider Monkey)
Mar-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace)
Mar-13-24 04:05PM	Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day (Business Wire)
Mar-12-24 04:08PM	Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study (Investor's Business Daily) -17.20%
03:05PM	Loading…
03:05PM	Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short (Investopedia)
11:06AM	Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails (Zacks)
09:30AM	Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? (InvestorPlace)
07:43AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Mar-11-24 04:46PM	UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study (Reuters)
04:13PM	Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study (Reuters)
04:05PM	Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia (Business Wire)
Feb-29-24 09:05AM	Acadia Pharmaceuticals to Participate in TD Cowens 44th Annual Health Care Conference on March 6, 2024 (Business Wire)
08:44AM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:05PM	Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch (Investor's Business Daily) -9.92%
09:12AM	Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down (Zacks)
Feb-27-24 05:20PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Zacks)
04:56PM	ACADIA Pharmaceuticals Inc. Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:27PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview (Business Wire)
08:16PM	Loading…
Feb-22-24 08:16PM	ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Feb-21-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-24 10:00AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-13-24 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-30-24 08:48PM	Acadia Announces Additions to Executive Team (Business Wire)
05:00PM	20 Countries With The Highest Number of Drug Trafficking in the World (Insider Monkey)
Jan-26-24 05:31PM	Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US (Insider Monkey)
Jan-25-24 08:42AM	10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts (Insider Monkey)
Jan-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-18-24 04:05PM	Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic (Business Wire)
Jan-12-24 05:02PM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 3,732 Shares (GuruFocus.com)
Dec-21-23 04:05PM	Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 (Business Wire)
Dec-18-23 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-23 09:24PM	Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID (pimavanserin) (Business Wire) +34.48%
04:14PM	Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug (Investor's Business Daily)
01:41PM	Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID (pimavanserin) Patent Litigation (Business Wire)
Nov-30-23 09:05AM	Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome (Business Wire)
Nov-27-23 09:05AM	Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimers Disease Psychosis (Business Wire)
Nov-21-23 11:03PM	Insider Sell Alert: EVP Brendan Teehan Sells Shares of ACADIA Pharmaceuticals Inc (GuruFocus.com)
05:00PM	Acadia Pharmaceuticals Announces Change in Research and Development Leadership (Business Wire)
Nov-17-23 09:40AM	Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year? (Zacks)
Nov-16-23 08:42AM	Implied Volatility Surging for On ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Nov-14-23 04:12PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-08-23 05:24PM	3 Biotech Stocks With the Strongest Clinical Pipelines (InvestorPlace)
Nov-04-23 01:10PM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 06:51PM	ACADIA Pharmaceuticals Inc. Reports Record Revenues in Q3 2023 (GuruFocus.com)
04:37PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview (Business Wire)
Oct-31-23 04:05PM	Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference (Business Wire)
Oct-26-23 10:02AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 09:05AM	Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program (Business Wire)
Oct-19-23 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023 (Business Wire)
Oct-18-23 05:00PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-10-23 10:49AM	Why Acadia Pharmaceuticals Stock Is Rising Today (Motley Fool) +7.73%
09:32AM	Rivian upgraded, Qorvo downgraded: Wall Street's top analyst calls (The Fly)
Oct-07-23 05:01AM	EVP, General Counsel, Secretary Austin Kim Sells 16,369 Shares of ACADIA Pharmaceuticals Inc (GuruFocus.com)
Sep-30-23 10:30AM	2 Growth Stocks I'd Buy on the Dip (Motley Fool)
Sep-22-23 06:23PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-23 04:05PM	Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications (Business Wire)
Aug-30-23 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-28-23 06:00PM	2 Supercharged Growth Stocks Billionaires Can't Stop Buying (Motley Fool)
Aug-22-23 08:30AM	Can This Red-Hot Biotech Stock Keep Beating the Broader Markets? (Motley Fool)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-14-23 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-04-23 12:36PM	Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform (Zacks)
Aug-02-23 04:26PM	Acadia: Q2 Earnings Snapshot (AP Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview (Business Wire)
Aug-01-23 07:30PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-23 11:21AM	Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts (Zacks)
Jul-24-23 04:05PM	Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer (Business Wire)
Jul-21-23 09:40AM	Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-19-23 04:04PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023 (Business Wire)
Jul-15-23 08:19AM	Analysts Just Published A Bright New Outlook For ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) (Simply Wall St.)
Jul-14-23 04:04PM	Acadia's Newest Drug Just Obliterated Sales Expectations; Shares Hit Two-Year High (Investor's Business Daily) +24.73%
11:41AM	Why Acadia Pharmaceuticals Stock Is Soaring Today (Motley Fool)
Jul-13-23 07:11PM	Why These 2 Biotech Stocks Made Big Moves Late Thursday (Motley Fool)
04:05PM	Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neurens NNZ-2591 in Rett Syndrome and Fragile X Syndrome (Business Wire)
Jun-26-23 05:00PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-13-23 04:05PM	Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome (Business Wire)
Jun-12-23 01:24PM	ACADIA Pharmaceuticals (NASDAQ:ACAD) delivers shareholders favorable 9.3% CAGR over 5 years, surging 3.1% in the last week alone (Simply Wall St.)
Jun-08-23 11:10AM	Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE (trofinetide) Efficacy and Safety in Patients with Rett Syndrome (Business Wire)
Jun-07-23 11:30AM	Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue? (Zacks)
05:58AM	3 Penny Stocks That Could Skyrocket in the Next 12 Months (InvestorPlace)
Jun-01-23 09:04AM	Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-08-23 05:25PM	Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:13PM	Acadia: Q1 Earnings Snapshot (AP Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview (Business Wire)
09:21AM	ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Is Matching Sentiment Around Its Revenues (Simply Wall St.)
May-05-23 04:04PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAVIS STEPHEN	CEO	Apr 08 '24	Sale	17.87	26,574	474,877	144,267	Apr 09 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '24	Sale	17.87	2,716	48,535	28,742	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Apr 08 '24	Sale	17.87	2,568	45,890	38,796	Apr 09 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '24	Sale	17.87	1,790	31,987	13,100	Apr 09 06:00 PM
DAVIS STEPHEN	CEO	Mar 27 '24	Sale	17.90	17,714	317,081	118,842	Mar 27 07:58 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	17.90	5,434	97,269	26,183	Mar 27 07:57 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Mar 27 '24	Sale	17.90	5,140	92,006	36,340	Mar 27 08:00 PM
DAVIS STEPHEN	CEO	Feb 26 '24	Sale	24.67	5,577	137,585	101,890	Feb 27 06:02 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 26 '24	Sale	24.67	772	19,045	21,067	Feb 27 06:13 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Feb 26 '24	Sale	24.67	624	15,394	31,432	Feb 27 06:10 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 26 '24	Sale	24.67	474	11,694	11,391	Feb 27 06:07 PM
DAVIS STEPHEN	CEO	Jan 08 '24	Sale	29.96	3,732	111,811	96,521	Jan 09 06:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Jan 08 '24	Sale	29.96	731	21,901	30,949	Jan 09 06:00 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Jan 08 '24	Sale	29.96	590	17,676	46,901	Jan 09 06:00 PM
Kihara James	Principal Accounting Officer	Dec 15 '23	Sale	28.30	2,000	56,600	11,025	Dec 15 07:37 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Nov 20 '23	Sale	22.64	5,108	115,645	20,486	Nov 21 06:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Nov 20 '23	Sale	22.64	4,960	112,294	30,393	Nov 21 06:00 PM
Kihara James	Principal Accounting Officer	Nov 20 '23	Sale	22.64	1,985	44,940	13,025	Nov 21 06:00 PM
DAVIS STEPHEN	CEO	Oct 06 '23	Sale	21.96	51,563	1,132,323	89,131	Oct 06 09:59 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Oct 06 '23	Sale	21.96	16,369	359,463	45,857	Oct 06 10:00 PM
Kihara James	Principal Accounting Officer	Sep 15 '23	Sale	25.88	2,000	51,760	10,778	Sep 19 06:31 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Aug 21 '23	Sale	29.00	10,000	289,970	15,682	Aug 23 07:31 PM
DAVIS STEPHEN	CEO	Jul 14 '23	Option Exercise	20.77	100,000	2,077,000	136,695	Jul 18 06:00 PM
DAVIS STEPHEN	CEO	Jul 14 '23	Sale	30.04	100,000	3,004,350	36,695	Jul 18 06:00 PM
DAVIS STEPHEN	CEO	Jul 12 '23	Sale	25.05	55,104	1,380,449	36,695	Jul 13 08:27 PM
DAVIS STEPHEN	CEO	Jul 11 '23	Sale	25.00	16,498	412,450	91,799	Jul 13 08:27 PM
Kihara James	Principal Accounting Officer	Jun 15 '23	Sale	24.15	2,000	48,300	9,144	Jun 16 04:38 PM
Brege Laura	Director	Jun 12 '23	Sale	24.87	4,500	111,906	13,502	Jun 14 05:14 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 08 '23	Option Exercise	0.00	1,893	0	23,798	Jun 12 08:48 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 08 '23	Sale	25.02	974	24,369	22,824	Jun 12 08:48 PM
BAKER BROS. ADVISORS LP	Director	May 24 '23	Buy	25.48	553,263	14,096,825	39,317,673	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 23 '23	Option Exercise	17.01	25,000	425,250	38,620,261	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 23 '23	Buy	25.41	209,053	5,312,458	38,811,515	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 22 '23	Buy	24.57	134,206	3,297,815	38,607,761	May 24 05:09 PM
Schneyer Mark C.	EVP, Chief Financial Officer	May 17 '23	Sale	22.50	15,310	344,475	21,905	May 19 06:48 PM
Teehan Brendan	EVP, COO, Head of Commercial	May 17 '23	Sale	22.50	14,869	334,552	24,356	May 19 06:43 PM
Kihara James	Principal Accounting Officer	May 17 '23	Sale	22.50	5,947	133,808	11,144	May 19 06:54 PM
DAVIS STEPHEN	CEO	May 01 '23	Sale	21.18	7,806	165,331	108,297	May 02 07:02 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	May 01 '23	Sale	21.18	917	19,422	25,513	May 02 07:06 PM
Teehan Brendan	EVP, COO, Head of Commercial	May 01 '23	Sale	21.18	548	11,607	9,487	May 02 07:04 PM
DAVIS STEPHEN	CEO	Apr 29 '23	Option Exercise	0.00	15,625	0	116,103	May 02 07:02 PM
Teehan Brendan	EVP, COO, Head of Commercial	Apr 29 '23	Option Exercise	0.00	1,567	0	10,035	May 02 07:04 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

HALO

Halozyme Therapeutics Inc.

ACAD

Acadia Pharmaceuticals Inc

Upgrade your FINVIZ experience